Intuitive's da Vinci 5 wins FDA cardiac clearance, targeting 160K procedures annually. A strategic return to where it all began in 2002.

Intuitive Surgical Returns to Its Roots: FDA Clears da Vinci 5 for Cardiac Surgery

Intuitive Surgical beats Q4 estimates by 12% with $2.53 EPS as da Vinci 5 placements surge 74%. What the guidance implies for 2026.

Intuitive Surgical Crushes Q4 Estimates as da Vinci 5 Adoption Accelerates

Intuitive Surgical beats Q4 by 11% with $2.53 EPS, but guides 2026 procedure growth down to 13-15% as tariffs eat 1.2% of revenue.

Intuitive Surgical posts record $10B revenue, beats Q4 estimates, but stock falls 3% as 2026 guidance disappoints and Ion system placements decline.